Anastrozole Tablet
Product Images NDC 50090-2453

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Anastrozole (NDC 50090-2453). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1 (Anastrozole Fig1)

Figure 1 (Anastrozole Fig1)
A line graph depicting disease-free survival over time in months for patients treated with anastrozole versus tamoxifen. The y-axis shows the proportion of patients alive and disease-free, while the x-axis represents time in months, up to 90 months. The graph includes a legend distinguishing the two treatments.*
FDA Label Image

Figure 2 (Anastrozole Fig2)

Figure 2 (Anastrozole Fig2)
A survival curve chart showing disease-free survival over 90 months for patients randomized to treatment with anastrozole or tamoxifen. The y-axis represents the proportion alive and disease-free, while the x-axis shows time in months. The chart includes a table of patient numbers at risk for each treatment group at various time points.*
FDA Label Image

Figure 3 (Anastrozole Fig3)

Figure 3 (Anastrozole Fig3)
A Kaplan-Meier curve comparing progression-free survival over 120 months between Anastrozole and Tamoxifen treatments. The x-axis represents time to event in months, and the y-axis shows the proportion progression-free. The graph includes a table of the number of patients at risk at various time points for both treatments.*
FDA Label Image

Figure 4 (Anastrozole Fig4)

Figure 4 (Anastrozole Fig4)
A Kaplan-Meier survival curve graph comparing the proportion of patients event-free over time (in months) for treatments with Anastrozole and Tamoxifen. The chart shows the proportion decreasing gradually from 0 to 120 months, with a table below listing the number of patients at risk at specified time points for each treatment group.*
FDA Label Image

Figure 5 (Anastrozole Fig5)

Figure 5 (Anastrozole Fig5)
A Kaplan-Meier survival curve chart comparing the proportion of patients not progressing over time (months) between two randomized treatments: Anastrozole and Tamoxifen. The x-axis represents time to progression in months, and the y-axis shows the proportion of patients without disease progression.*
FDA Label Image

Figure 6 (Anastrozole Fig6)

Figure 6 (Anastrozole Fig6)
Kaplan-Meier survival curve chart comparing progression over time (months) among randomized treatment groups for Anastrozole and Tamoxifen. The y-axis shows the proportion not progressed, and the x-axis shows time to progression in months.*
FDA Label Image

Chemical Structure For Anastrozole (Anastrozole Str)

Chemical Structure For Anastrozole (Anastrozole Str)
Chemical structure of anastrozole, showing its molecular framework including the triazole ring and aromatic ring with nitrile and methyl groups.*
FDA Label Image

Label Image (Lbl500902453)

Label Image (Lbl500902453)
Label for Anastrozole 1 mg oral tablets, a human prescription drug by A-S Medication Solutions. The label lists the product NDC as 50090-2453-0 and notes each tablet contains 1 mg of anastrozole. Storage instructions indicate to keep at 68 to 77 degrees Fahrenheit. The package contains 30 tablets.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.